DIC. Bert Vandewiele Fellow Critical Care 23 May 2011
|
|
- Beverly Anderson
- 5 years ago
- Views:
Transcription
1 DIC Bert Vandewiele Fellow Critical Care 23 May 2011
2 Dissiminated Intravascular Coagulopathie 11/3/2011 Dr. Bert Vandewiele 2
3 Dissiminated Intravascular Coagulopathie = Consumption coagulopathie = Defibrination syndrome Incidence: 1 % Hospital Admissions Prognosis Underlying disease 40-80% mortality in patients with severe sepsis, trauma or burns DIC is NOT a disease, it is a complication of an underlying disorder 11/3/2011 Dr. Bert Vandewiele 3
4 DIC 1. Pathogenesis 2. Etiology 3. Clinical Features 4. Diagnosis 5. Treatment 11/3/2011 Dr. Bert Vandewiele 4
5 1. Pathogenesis Acute or chronic Bleeding Trombosis 11/3/2011 Dr. Bert Vandewiele 5
6 The clotting Cascade Furie B, Furie B.C. Mechanisms of Thrombus Formation N Engl J Med 2008; 359: /3/2011 Dr. Bert Vandewiele 6
7 1. Pathogenesis: trombosis 11/3/2011 Dr. Bert Vandewiele 7
8 1. Pathogenesis: bleeding Coagulation factor deficiency Consumption of coagulation factors Compensatory mechanisms compromised Liver Vit K deficiency Increased losses due to bleeding Thrombocytopenia Thrombin induced platelet aggregation Microangiopathic hemolytic anemia Akca, S., Haji-Michael, P., de, M.A., Suter, P., Levi, M. & Vincent, J.L. (2002) Time course of platelet counts in critically ill patients. Critical Care Medicine, 30, /3/2011 Dr. Bert Vandewiele 8
9 1. Pathogenesis: Bleeding PLASMIN FIBRIN DEGRADATION PRODUCTS (FDP) Interfere with normal fibrin polymerization Bind to glycoprotein IIb/IIIa fibrinogen receptor on platelets PROTEOLYTIC ACTIVITY Proteolytic degradation of fibrinogen Proteolytic degradation of clotting factors 11/3/2011 Dr. Bert Vandewiele 9
10 11/3/2011 Dr. Bert Vandewiele 10
11 1. Pathogenesis 11/3/2011 Dr. Bert Vandewiele 11
12 1. Pathogenesis: Acute versus chronic DIC Chronic Acute Event Slow activation Event Brisk Explosive Propagation Production procoagulants Liver compensates clotting factors Bone marrow compensates platelets Propagation Depletion of clotting factors Depletion of platelets and fibrinogen FDP interfere with hemostasis effect trombosis Trousseau Syndrome effect Bleeding diathesis Microangiopathic hemolytic anemia 11/3/2011 Dr. Bert Vandewiele 12
13 2. Etiology Sepsis/severe infection (any microorganism) Trauma (e.g. polytrauma, neurotrauma, fat embolism).. Organ destruction (e.g. severe pancreatitis). Malignancy: solid tumours myeloproliferative/lymphoproliferative malignancies. Obstetrical calamities: amniotic fluid embolism abruptio placentae. Vascular abnormalities: Kasabach Merrit syndrome large vascular aneurysms severe hepatic failure. Severe toxic or immunological reactions: snake bites recreational drugs transfusion reactions transplant rejection. Etiology (alternatively aetiology) is the study of causation, or origination. The word is derived from the Greek αἰτιολογία, aitiologia, "giving a reason for" (αἰτία, aitia, "cause"; and - λογία, -logia). Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145:24. 11/3/2011 Dr. Bert Vandewiele 13
14 2.1 Sepsis Incidence 30-50% Gram negative sepsis Meningococcal sepsis (Gram positive sepsis/viral infections) Pathophysiology Tissue Factor Thrombin generation (direct via endotoxins or other membrane LPS, IL6-mediated, high levels of microparticles with TF) Suppression of normal antithrombotic mechanisms (TNFα) Associated conditions Reduced blood flow Tissue damage Impaired hepatic perfusion (decreased hepatic clearance of procoagulants) 11/3/2011 Dr. Bert Vandewiele 14
15 2.2 Trauma and extensive surgery Incidence > 50% in trauma patients with SIRS % patients with severe head injury Pathophysiology Tissue enzymes from damaged tissue Phospholipids from damaged tissue Activation of cytokine networks Associated conditions 11/3/2011 Dr. Bert Vandewiele 15
16 2.3 Malignancy Incidence 15% Acute promyelocytic leukemia (bleeding) Common in solid tumors Trousseau s syndrome Pathophysiology Tissue factor expressed on circulating tumor cells Cancer procoagulant: activates factor X directly 11/3/2011 Dr. Bert Vandewiele 16
17 2.4 Obstetrical complications Incidence > 50% Amniotic fluid embolism > 50% Abruptio Placenta 20% HELLP 7% Preeclampsia Septic abortion/dead fetus syndrome Pathophysiology Leakage of tromboplastin like material 11/3/2011 Dr. Bert Vandewiele 17
18 3. Clinical features Bleeding (64%) Renal Dysfunction (25%) Hepatic dysfunction (19%) Respiratory dysfunction (16%) Shock (14%) Thromboembolism (7%) Central nervous system involvement (2%) 11/3/2011 Dr. Bert Vandewiele 18
19 3. Clinical features: bleeding Petechiae and ecchymoses Blood oozing: Wound sites Intravenous lines/catheters Mucosal surfaces Life-Threatening: GASTROINTESTINAL/LUNGS/CNS Post-surgical blood oozing: Catheters Drains Tracheostomies Serous cavities 11/3/2011 Dr. Bert Vandewiele 19
20 3. Clinical features: Acute renal failure 25-40% of patients Two mechanisms Microthrombosis of afferent arterioles Cortical ischemia and necrosis Hypotension and or sepsis Acute tubular necrosis Differentiate from TTP-HUS! 11/3/2011 Dr. Bert Vandewiele 20
21 DIC vs TTP-HUS Test DIC TTP Platelet count Decreased Decreased Fibrinogen Decreased Normal Fibrin Degradation Products (FDP) Increased Normal D-dimer Increased Normal Antithrombin Decreased Normal Schistocytes Present Present Plasma clotting times Prolonged Normal Euglobin Lysis time Shortened Normal 11/3/2011 Dr. Bert Vandewiele 21
22 Schistocyte 11/3/2011 Dr. Bert Vandewiele 22
23 3. Clinical features: hepatic dysfunction Jaundice Increased bilirubin production secondary to hemolysis Due to the underlying disease 11/3/2011 Dr. Bert Vandewiele 23
24 3. Clinical features: Pulmonary disease Primary due to damage to the pulmonary vascular endothelium As a consequence of the underlying disease. 11/3/2011 Dr. Bert Vandewiele 24
25 4. Diagnosis Which tests to use? Acute DIC vs Chronic DIC Differential diagnosis Acute DIC versus severe liver disease DIC versus TTP-HUS DIC versus fibrinogenolysis DIC versus Heparin Induced Thrombocytopenia 11/3/2011 Dr. Bert Vandewiele 25
26 4. Diagnosis There is no single laboratory test to diagnose DIC! DIC is an extremely dynamic situation! The whole clinical picture +? Laboratory tests 11/3/2011 Dr. Bert Vandewiele 26
27 4. Diagnosis 1. Platelet count 2. Fibrin Degradation products and D-dimers 3. PT and aptt 4. Fibrinogen 5. Blood film 6. Other markers of hemostasis 7. Scoring system 11/3/2011 Dr. Bert Vandewiele 27
28 4.1 Platelet count Reduction in platelet count or clear downward trend Sensitive (Thrombocytopenia 98% patients with DIC) (Platelet count < in 50% DIC patients) Not specific (Sepsis/Leukemia/... thrombocytopenia) Correlates strongly with markers of thrombin generation (thrombin-induced platelet aggregation is mainly responsible for platelet consumption). 11/3/2011 Dr. Bert Vandewiele 28
29 4.2 Fibrin Degradation products and D- dimers Increased fibrinolytic activity Fibrin Degradation Products FDP (not specific) D-dimer (more specific) BUT Other disease associated with FDP and D-dimers Liver and kidney impairment influence the levels Maybe Soluble Fibrin Monomer (Is only generated intravascularly by the thrombin action on fibrinogen) 11/3/2011 Dr. Bert Vandewiele 29
30 4.3 PT and aptt Prolonged in about 50-60% of cases of DIC, due to consumption, impaired synthesis and loss of coagulation proteins PT measures extrensic and common pathway Factor VII, X, V and prothrombin (II) aptt measures intrinsic and common pathway XII, XI, IX and VIII, X, V and prothrombin (II) Sometimes shortened Circulating activated clotting factors) PT INR (Only validated for OAC monitoring) 11/3/2011 Dr. Bert Vandewiele 31
31 4.4 Fibrinogen Theoretically useful BUT It is an acute phase reactant (fibrinogen levels were normal in up to 58% patients with DIC) Interference on the assay for fibrinogen level by FDP Sequential measurements might be more useful 11/3/2011 Dr. Bert Vandewiele 32
32 4.5 Blood film Fragmented Red blood cells Not specific Not sensitive Consider other causes of TMA (thrombotic microangiopathy) 11/3/2011 Dr. Bert Vandewiele 33
33 4.6 Other markers of haemostasis Natural anticoagulants Antithrombin Protein C Protein S TEG Atypical light transmittance profile on the aptt 11/3/2011 Dr. Bert Vandewiele 34
34 4.7 Scoring System Taylor, F.B., Jr,, Toh, C.H., Hoots, W.K., Wada, H. & Levi, M. (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis., 86, /3/2011 Dr. Bert Vandewiele 35
35 4. Diagnosis: Acute versus chronic DIC Parameter Acute Decompensated DIC Chronic Compensated DIC Platelet count Reduced Variable Prothrombin time Prolonged Normal Activated partial tromboplastin time Prolonged Normal Thrombin time Prolonged Normal Plasma fibrinogen Reduced Normal-Elevated Plasma factor V Reduced Normal Plasma factor VIII Reduced Normal Fibrin Degradation Products (FDP) Elevated Elevated D-dimer Elevated Elevated 11/3/2011 Dr. Bert Vandewiele 36
36 4. Diagnosis: Differential Acute DIC versus severe liver disease DIC versus TTP-HUS DIC versus fibrinogenolysis DIC versus Heparin Induced Thrombocytopenia 11/3/2011 Dr. Bert Vandewiele 37
37 5. Treatment The underlying disease The Underlying disease The Underlying disease The Underlying disease The Underlying disease 11/3/2011 Dr. Bert Vandewiele 38
38 5. Treatment: Besides the underlying disease 1. Platelets 2. Plasma 3. Anticoagulants 4. Anticoagulant factor concentrates 5. Antifibrinolytic treatment 11/3/2011 Dr. Bert Vandewiele 39
39 5.1 Platelets Dont make the decision on laboratory results! There is no evidence to support the administration of platelets in non bleeding patients or patients not at high risk of bleeding Platelets < bleeding OK Platelets < non bleeding OK Patient at high risk for bleeding/procedure?? Dose: 1-2 units / 10kg / day Monitor the respons of component therapy 11/3/2011 Dr. Bert Vandewiele 40
40 5.2 Plasma Dont make the decision on laboratory results! Bleeding? Risk for bleeding? Procedure? Dose: ml / kg / day (Average male liter FFP / day ) Coagulation factor concentrates Small volumes Lack factor V Risk for worsening DIC due to activated clotting factors Cryoprecipitate as source of fibrinogen (3000 mg) if fibrinogen < 1g/l) Monitor the respons of component therapy 11/3/2011 Dr. Bert Vandewiele 41
41 5.3 Anticoagulants There are no clinical randomised controlled trials proving an improvement in clinically relevant outcomes Theoretically and experimentally heparin can at least partly inhibit the activation of coagulation in DIC. (anti factor Xa and thrombin activity) VTE prophylaxis with UFH or LMWH has become standard care in patients with DIC Tissue Factor Pathway Inhibitor (TFPI), was promising, but no benefit in phase III trial 11/3/2011 Dr. Bert Vandewiele 42
42 5.4 Anticoagulant factor concentrates Antithrombin concentrate Laboratory changes No clinical changes apc = Activated Protein C Effective in patients with DIC AND Sepsis Stop if invasive procedures necessary Risk for major bleeding Severe thrombocytopenia is a contraindication Dose: Continuous infusion 24 µg/kg/h for 4 days 11/3/2011 Dr. Bert Vandewiele 43
43 5.5 Antifibrinolytic treatment Generally not recommended Exception: if primary or secondary hyperfibrinolysis dominates the clinical picture Acute Promyelocytic Leukemia Prostate cancer Dose: lysine analogue, tranexamic acid 1g every 8 hours 11/3/2011 Dr. Bert Vandewiele 44
44 References Furie B, Furie B.C. Mechanisms of Thrombus Formation N Engl J Med 2008; 359: Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145:24. Akca, S., Haji-Michael, P., de, M.A., Suter, P., Levi, M. & Vincent, J.L. (2002) Time course of platelet counts in critically ill patients. Critical Care Medicine, 30, Levi, M. & Ten, C.H. (1999) Disseminated intravascular coagulation. New England Journal of Medicine, 341, Taylor, F.B., Jr,, Toh, C.H., Hoots, W.K., Wada, H. & Levi, M. (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis., 86, /3/2011 Dr. Bert Vandewiele 45
Approach to disseminated intravascular coagulation
Approach to disseminated intravascular coagulation Khaire Ananta Shankarrao 1, Anil Burley 2, Deshmukh 3 1.MD Scholar, [kayachikitsa] 2.Professor,MD kayachikitsa. 3.Professor and HOD,Kayachikitsa. CSMSS
More informationDisseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department
Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department Disseminated intravascular coagulation (DIC, consumptive coagulopathy) is a clinicopathologic
More informationEDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION
EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationACQUIRED COAGULATION ABNORMALITIES
ACQUIRED COAGULATION ABNORMALITIES ACQUIRED COAGULATION ABNORMALITIES - causes 1. Liver disease 2. Vitamin K deficiency 3. Increased consumption of the clotting factors (disseminated intravascular coagulation
More informationDisseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS
به نام خدا Disseminated Intravascular Coagulation M.Bahmanpour MD Assistant professor IUMS Algorithm for Diagnosis of DIC DIC Score factor score Presence of known underlying disorder No= 0 yes=2 Coagolation
More informationDISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital
DISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital Disseminated intravascular coagulation (DIC) Disseminated
More informationHEME 10 Bleeding Disorders
HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional
More informationJohn Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation
More informationDisseminated Intravascular Coagulation (DIC) Seminar. Ron Kopilov 4 th year Medical Student, Tel Aviv University Internal Medicine A 8.3.
Disseminated Intravascular Coagulation (DIC) Seminar Ron Kopilov 4 th year Medical Student, Tel Aviv University Internal Medicine A 8.3.2012 1 Our plan: Understand the pathophysiology Identify risk factors
More informationMANAGEMENT OF COMMON BLEEDING DISORDERS. Auro Viswabandya Department of Haematology, CMC, Vellore
MANAGEMENT OF COMMON BLEEDING DISORDERS Auro Viswabandya Department of Haematology, CMC, Vellore BLOOD CLOT : PRIMARY HAEMOSTASIS (Platelets) + SECONDARY HAEMOSTASIS (Coagulation Factors) HAEMOSTATIC DISORDERS
More informationCoagulation, Haemostasis and interpretation of Coagulation tests
Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect
More informationHeme (Bleeding and Coagulopathies) in the ICU
Heme (Bleeding and Coagulopathies) in the ICU General Topics To Discuss Transfusions DIC Thrombocytopenia Liver and renal disease related bleeding Lack of evidence in managing critical illness related
More informationAgent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min
Nanik (Nayri) Hatsakorzian Pharm.D/MPH candidate 2014 Touro University College of Pharmacy CA Bleeding Reversal Agents Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute lung injury (ALI) transfusion-related, 363 372. See also Transfusion-related acute lung injury (TRALI) ALI. See Acute lung injury
More informationHematology Review. CCRN exam. The Coagulation Cascade. The Coagulation Cascade. Components include: Intrinsic pathway Extrinsic pathway Common pathway
CCRN exam Hematology Review CCRN Review October 2013 Department of Critical Care Nursing Hematology is 2% of the exam Focus on coagulation cascade, DIC, and HIT Anatomy of the hematologic system Bone marrow
More informationCoagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU
Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate
More informationPart IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
More informationApproach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate
Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:
More informationL iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche
L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University
More informationLAMA SHATAT TTP, ITP, DIC
TTP, ITP, DIC Reduction in platelet number (thrombocytopenia) constitutes an important cause of generalized bleeding. A count less than 100,000 platelets/μl is generally considered to constitute thrombocytopenia.
More informationThursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III
REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels
More informationBLEEDING DISORDERS Simple complement:
BLEEDING DISORDERS Simple complement: 1. Select the statement that describe the thrombocytopenia definition: A. Marked decrease of the Von Willebrandt factor B. Absence of antihemophilic factor A C. Disorder
More informationUNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.
UNIT VI Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav Hemostasis: Prevention of Blood Loss Vascular constriction Formation of a platelet plug Formation of a blood
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationThrombosis and emboli. Peter Nagy
Thrombosis and emboli Peter Nagy A thrombus is any solid object developing from the blood in vivo within the vascular system or heart. Thrombosis is hemostasis in the wrong place. Major components, forms:
More informationCOAGULATIONS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin)
COAGULATIONS Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin) Haemostasis-blood must be maintained in a fluid state in order to function as a transport system, but must be able to solidify to form a clot following
More informationWhat are blood clots?
What are blood clots? Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner Westcliffe Medical Group Created 5/31/18 Dr. Matthew
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationHemostasis and thrombosis in patients with liver disease. Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands
Hemostasis and thrombosis in patients with liver disease Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands Importance of the liver in hemostasis Synthesis of Coagulation factors Fibrinolytic proteins
More informationThe frequency of disseminated intravascular. Zanco J. Med. Sci., Vol. 18, No. (2),
The frequency of disseminated intravascular coagulopathy in newly diagnosed adult patients with haematological malignancies attending Nanakaly Hospital in Erbil Received: 17/1/2013 Accepted: 23/7/2013
More informationINHERITED COAGULOPATHY
Disorder Etiology Pathophysiology and Presentation Lab Findings and Diagnosis Treatment INHERITED COAGULOPATHY HEMOPHILIA A and B Hemophilia A: deficiency in XIII (85%) Hemophilia B: deficiency in IX (15%)
More informationDisseminated Intravascular Coagulation: A Case-Based Approach
Disseminated Intravascular Coagulation: A Case-Based Approach Thursday, May 17 9:45 11 am Note one action you ll take after attending this session: Rebecca Martin, BSN, RN, OCN, BMTCN Staff RN/Educator
More informationPrimary Exam Physiology lecture 5. Haemostasis
Primary Exam Physiology lecture 5 Haemostasis Haemostasis Body s response for the prevention and cessation of bleeding. Broadly consists of: Primary Haemostasis - vascular spasm and platlet plug formation
More informationPCCN Review Hematology
PCCN Review Hematology Leanna R. Miller, RN, MN, CCRN-CMC, PCCN-CSC CEN, CNRN, CMSRN, NP Education Specialist LRM Consulting Nashville, TN Anemia Definition reduction in RBC concentration Causes iron deficiency
More informationEffect of under filling tube
Effect of under filling tube 2 What constitutes underfilling? A 4.5ml vacutainer collection tube should contain at least 4ml of blood Less than that could give falsely prolonged clotting times ALSO be
More informationMASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE
MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE CONTENTS Definition Indications Transfusion trigger Massive transfusion protocol Complications DEFINITION Massive transfusion:
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal tumors, in children, 530 531 Alkalinization, in tumor lysis syndrome, 516 Allopurinol, in tumor lysis syndrome, 515 Anaphylaxis, drug
More informationThe Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (9), Page
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (9), Page 5210-5214 The Utility of Fibrinogen/C-reactive protein Ratio versus D-dimer and Fibrin Degradation Product in Diagnosis of Overt
More informationTopics of today lectures: Hemostasis
Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms of hemostasis - Vascular contraction - Platelets plug - Blood coagulation (clotting) - Structure and functions of platelets - Blood
More informationHemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.
Hemodynamic Disorders, Thrombosis, and Shock Richard A. McPherson, M.D. Edema The accumulation of abnormal amounts of fluid in intercellular spaces of body cavities. Inflammation and release of mediators
More informationManaging coagulopathies in critical care
Managing coagulopathies in critical care Prof Beverley Hunt Thrombosis & Haemostasis, King s College Consultant, Guy s & St Thomas Trust Medical Director of Lifeblood: the thrombosis charity Twitter @bhwords
More informationThings to never miss in the office. Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC
Things to never miss in the office Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC Presenter Disclosure Faculty / Speaker s name: Brett Houston / Leonard Minuk Relationships with commercial
More informationHaematological Emergencies (Part 1) Ray Mun Koo Haematology Advanced Trainee Canberra Hospital
Haematological Emergencies (Part 1) Ray Mun Koo Haematology Advanced Trainee Canberra Hospital Case Number 1 43 year old male presenting with fevers, abdominal distension and weight gain over 2 weeks.
More informationHaemostasis & Coagulation disorders Objectives:
Haematology Lec. 1 د.ميسم مؤيد علوش Haemostasis & Coagulation disorders Objectives: - Define haemostasis and what are the major components involved in haemostasis? - How to assess the coagulation status?
More informationMANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY
MANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY 19th ANNUAL CONTROVERSIES AND PROBLEMS IN SURGERY Thabo Mothabeng General Surgery: 1 Military Hospital HH Stone et al. Ann Surg. May 1983; 197(5):
More informationThis slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion
This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms
More informationManaging Coagulopathy in Intensive Care Setting
Managing Coagulopathy in Intensive Care Setting Dr Rock LEUNG Associate Consultant Division of Haematology, Department of Pathology & Clinical Biochemistry Queen Mary Hospital Normal Haemostasis Primary
More informationTransfusion in major bleeding: new insights. Gert Poortmans
Transfusion in major bleeding: new insights Gert Poortmans Trauma Cardiac Surgery Major Surgery with ongoing blood loss Burn Surgery Lethal Triad Polytransfusion: definitions Coagulation Coagulopathy of
More informationChapter 3. Haemostatic abnormalities in patients with liver disease
Chapter 3 Haemostatic abnormalities in patients with liver disease Ton Lisman, Frank W.G. Leebeek 1, and Philip G. de Groot Thrombosis and Haemostasis Laboratory, Department of Haematology, University
More informationChapter 19. Hemostasis
Chapter 19 Hemostasis Hemostasis Hemostasis is the cessation of bleeding stopping potentially fatal leaks important in small blood vessels not effective in hemorrhage excessive bleeding from large blood
More informationActive date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:
Guideline Title: Guidelines for the management of warfarin reversal [key words : Beriplex, Octaplex, PCC, vitamin K, anticoagulant, anticoagulation] Authors: Dr Sarah Allford, Consultant Haematologist
More informationGeneral approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013
General approach to the investigation of haemostasis Jan Gert Nel Dept. of Haematology University of Pretoria 2013 Clinical reasons to investigate haemostasis Investigating a clinically suspected bleeding
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationCoagulation: Consultative Hemostasis
Coagulation: Consultative Hemostasis Julie Hambleton, Lawrence L. Leung, and Marcel Levi Clinical hematologists are frequently consulted for the care of hospitalized patients with complicated coagulopathies.
More informationOnline Supplementary Data. Country Number of centers Number of patients randomized
A Randomized, Double-Blind, -Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular
More informationEffective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)
1 of 5 Policy #: 702 (PHL-702-05) Effective Date: 9/30/2004 Reviewed Date: 8/1/2016 Subject: TRANSFUSION GUIDELINES Approved by: Laboratory Director, Jerry Barker (electronic signature) Approved by: Laboratory
More informationRip roaring hematologic dysfunction from solid organ malignancies
Rip roaring hematologic dysfunction from solid organ malignancies A tale from UWMC hematology consult service in 4/2017 Lindsay Hannan, MD MSPH Discussant: Dr. Sioban Keel. Main objectives 1) DIC scoring
More informationPathology note 8 BLEEDING DISORDER
Pathology note 8 BLEEDING DISORDER Slide75 ( Types of clotting factors deficiency): Today we will talk about public public factor deficiency it could be acquired or inherited, acquired diseases are more
More informationTRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.
More informationTitle. Author(s)Hayakawa, Mineji; Gando, Satoshi; Hoshino, Hirokatsu. CitationClinical and Applied Thrombosis/Hemostasis, 13(1): 6. Issue Date
Title A Prospective Comparative Study of Three Sets of Cri vs Japanese Criteria Author(s)Hayakawa, Mineji; Gando, Satoshi; Hoshino, Hirokatsu CitationClinical and Applied Thrombosis/Hemostasis, 13(1):
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationBleeding Disorders: (Hemorrhagic Diatheses) Tests used to evaluate different aspects of hemostasis are the following:
Bleeding Disorders: (Hemorrhagic Diatheses) Excessive bleeding can result from: 1. Increased fragility of vessels. 2. Platelet deficiency or dysfunction. 3. Derangement of coagulation. 4. Combinations
More informationUNIVERSITAS PELITA HARAPAN
Review Article Disseminated Intravascular Coagulation Jane Olivia Lorens 1, Andree Kurniawan 2 1 Faculty of Medicine, Pelita Harapan Uniersity, Karawaci, Tangerang, Banten, Indonesia 2 Internal Medicine,
More informationHaemorrhagic Disorders. Dr. Bashar Department of Pathology Mosul Medical College
Haemorrhagic Disorders Dr. Bashar Department of Pathology Mosul Medical College Hemorrhagic Disorders These include Disorders of platelets. Disorders of blood vessels. Disorders of coagulation & fibrinolysis.
More informationC h a p t e r 5 0 Management of Disseminated Intravascular Coagulation
C h a p t e r 5 0 Management of Disseminated Intravascular Coagulation SK Bichile Professor and Head, Department of Haematology, TN Medical College and BYL Nair Hospital, Mumbai Introduction Disseminated
More informationIntroduction to coagulation and laboratory tests
Introduction to coagulation and laboratory tests Marc Jacquemin Special Haemostasis Laboratory Center for Molecular and Vascular Biology University of Leuven Coagulation in a blood vessel: fibrin stabilises
More informationAssessing thrombocytopenia in the intensive care unit: The past, present, and future
Assessing thrombocytopenia in the intensive care unit: The past, present, and future Ryan Zarychanski MD MSc FRCPC Sections of Critical Care and of Hematology, University of Manitoba Disclosures FINANCIAL
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationBlood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )
Blood coagulation and fibrinolysis Blood clotting (HAP unit 5 th ) Vessel injury Antithrombogenic (Favors fluid blood) Thrombogenic (Favors clotting) 3 Major systems involved Vessel wall Endothelium ECM
More informationMajor Haemorrhage Protocol. Commentary
Hairmyres Hospital Monklands Hospital Wishaw General Hospital Major Haemorrhage Protocol Commentary N.B. There is a separate NHSL protocol for the Management of Obstetric Haemorrhage Authors Dr Tracey
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationLifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO.
LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA 1011.02 Transfusion Criteria Version#2 Department POLICY NO. PAGE NO. Blood Bank Quality Assurance Manual
More informationChallenges in Coagulation
Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from
More informationDiagnosis of hypercoagulability is by. Molecular markers
Agenda limitations of clinical laboratories to evaluate hypercoagulability and the underlying cause for thrombosis what is the INR the lupus anticoagulant and the antiphospholipid antibody syndrome hassouna
More informationDocument Title: Hemostasis: Platelet and Coagulation Disorders. Author(s): Joseph H. Hartmann (University of Michigan), DO 2012
Project: Ghana Emergency Medicine Collaborative Document Title: Hemostasis: Platelet and Coagulation Disorders Author(s): Joseph H. Hartmann (University of Michigan), DO 2012 License: Unless otherwise
More informationBleeding and Thrombotic Disorders. Kristine Krafts, M.D.
Bleeding and Thrombotic Disorders Kristine Krafts, M.D. Bleeding and Thrombotic Disorders Bleeding disorders von Willebrand disease Hemophilia A and B DIC TTP/HUS ITP Thrombotic disorders Factor V Leiden
More informationBlood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus.
Blood clotting It is the conversion, catalyzed by thrombin, of the soluble plasma protein fibrinogen (factor I) into polymeric fibrin, which is deposited as a fibrous network in the primary thrombus. Thrombin
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationThrombosis. Dr. László Terézia
Thrombosis Dr. László Terézia HYPERCOAGULABILITY THROMBOSIS BLOODFLOW ENDOTHEL VIRCHOW ENDOTHEL INJURY L. ventricle: Arteries: surgery infection prosthetic valve hypertension irradiation chemical: cigarette
More informationTRANSFUSIONS FIRST, DO NO HARM
TRANSFUSIONS FIRST, DO NO HARM BECAUSE BLOOD CAN KILL 7 TRALI DEATHS SINCE 2002 WMC 5 women BECAUSE In OB you are transfusing 2 instead of 1 BECAUSE BLOOD IS A LIQUID TRANSPLANT RISKS versus BENEFITS versus
More informationSECTION XIX HEMATOLOGIC AND ONCOLOGIC DISEASE AND DYSFUNCTION CHAPTER 170 COAGULATION DISORDERS IN THE INTENSIVE CARE UNIT OVERVIEW OF COAGULATION
SECTION XIX HEMATOLOGIC AND ONCOLOGIC DISEASE AND DYSFUNCTION CHAPTER 170 COAGULATION DISORDERS IN THE INTENSIVE CARE UNIT ROBERT I. PARKER This chapter focuses on various pathophysiologic conditions associated
More informationWhen should I transfuse platelets and plasma for children? Dr Liz Chalmers. Consultant Paediatric Haematologist Royal Hospital for Children Glasgow
When should I transfuse platelets and plasma for children? Dr Liz Chalmers Consultant Paediatric Haematologist Royal Hospital for Children Glasgow When should I transfuse platelets and plasma in children?
More informationADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL
Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic
More informationHemostasis. Clo)ng factors and Coagula4on NORMAL COAGULATION. Overview of blood coagula4on. The Cascade Theory 5/1/12. Clot
Hemostasis Clo)ng factors and Coagula4on Dr Badri Paudel www.badripaudel.com Hemostasis is defined as a property of circula4on whereby blood is maintained within a vessel and the ability of the system
More informationBleeding Disorders HOPE Maram Al-anbar
Bleeding Disorders HOPE Maram Al-anbar 9-9 - 2014 ^^ Attention Please ^^ We ( correction team of pediatric package^hope/2010^ ) had decided to make one lecture of bleeding disorders in place of the two
More informationContents. Contributors. Reviewers. Acknowledgements I CARDIOVASCULAR COMPLICATIONS
Contributors Reviewers Acknowledgements Preface xii xvi xvii xviii I CARDIOVASCULAR COMPLICATIONS 1 Cardiac Complications of Cancer and Anticancer Treatment 3 Introduction 3 Malignant Pericardial Effusion
More informationHemostasis Haemostasis means prevention of blood loss from blood vessels.
1 Hemostasis Haemostasis means prevention of blood loss from blood vessels. Bleeding is stopped by several mechanisms, which are: 1. Local vasoconstriction 2. Formation of platelet plug 3. Blood coagulation
More informationBleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph
Bleeding Disorders Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph Normal hemostasis The normal hemostatic response involves interactions among: The blood vessel wall (endothelium)
More informationShock, Hemorrhage and Thrombosis
Shock, Hemorrhage and Thrombosis 1 Shock Systemic hypoperfusion due to: Reduction in cardiac output Reduction in effective circulating blood volume Hypotension Impaired tissue perfusion Cellular hypoxia
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationHemostasis Haemostasis means prevention of blood loss from blood vessels.
١ Hemostasis Haemostasis means prevention of blood loss from blood vessels. Bleeding is stopped by several mechanisms, which are: 1. Local vasoconstriction 2. Formation of platelet plug 3. Blood coagulation
More informationAortic Aneurysm-associated Disseminated Intravascular Coagulation that Responded Well to a Switch from Warfarin to Rivaroxaban
doi: 10.2169/internalmedicine.8666-16 http://internmed.jp CASE REPORT Aortic Aneurysm-associated Disseminated Intravascular Coagulation that Responded Well to a Switch from Warfarin to Rivaroxaban Yasuko
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Anemia(s), 412 426 categories in morphologic approach to, macrocytic, 412 414 microcytic, 412 414 normocytic, 412 413 categorizing, 412
More informationManagement of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH
Journal of Thrombosis and Haemostasis, 13: 1 5 DOI: 10.1111/jth.12838 RECOMMENDATIONS AND GUIDELINES Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationPathogenesis and diagnosis of disseminated intravascular coagulation
Received: 31 December 2017 Accepted: 07 February 2018 DOI: 10.1111/ijlh.12830 REVIEW ARTICLE Pathogenesis and diagnosis of disseminated intravascular coagulation M. Levi 1,2 1 Department of Medicine, University
More informationApproach To A Bleeding Patient
ABDUL MAJEED, RAHUL RAJEEV REVIEW ARTICLE INTRODUCTION Hemostasis is the process of forming clots in the walls of damaged blood vessels and preventing blood loss while maintaining blood in a fluid state
More informationDr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN
Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN The student should be able:» To identify the mechanism of homeostasis and the role of vessels, platelets
More informationTRAUMA RESUSCITATION. Dr. Carlos Palisi Dr. Nicholas Smith Liverpool Hospital
TRAUMA RESUSCITATION Dr. Carlos Palisi Dr. Nicholas Smith Liverpool Hospital First Principles.ATLS/EMST A- Airway and C-spine B- Breathing C- Circulation and Access D- Neurological deficit E- adequate
More informationPLASMA PRODUSTS IN CRITICAL CARE MEDICINE
PLASMA PRODUSTS IN CRITICAL CARE MEDICINE Paul F. W. Strengers Introduction Plasma from blood donors is the source for the preparation of a number of medicinal products, with a wide range of clinical indications.
More information